Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MACH-1 FAP colon cancer vaccine
- Development stage
- Preclinical
- Lead developer
- Orlance
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Gene Therapies
- Administration
- Epidermal
01
Overview
MACH-1 FAP colon cancer vaccine is a preclinical nucleic acid (DNA) vaccine being developed by Orlance for the treatment and prevention of Familial Adenomatous Polyposis (FAP) and associated colon cancer. The vaccine utilizes Orlance's proprietary MACH-1 (Micro-particle Accelerated Cell Harnessing) platform, which is an epidermal powdered gene gun delivery system. This technology delivers DNA-coated gold microparticles directly into the skin's epidermal layer, targeting Langerhans cells to induce a potent and systemic immune response. By delivering the genetic material directly into the cytoplasm of cells in the skin, the platform aims to overcome the delivery challenges typically associated with traditional DNA vaccines, potentially offering a more effective immunotherapy for colorectal malignancies.
- Other names
- Orlance FAP vaccineMACH-1 epidermal DNA vaccine for FAPMACH1 epidermal DNA vaccine for FAPMACH 1 epidermal DNA vaccine for FAP
02
Targets
FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on MACH-1 FAP colon cancer vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MACH-1 FAP colon cancer vaccine.